EGFR and non-small cell lung carcinoma: In this study, we reviewed 71 consecutive patients at TVGH to investigate risk factors affecting oncological outcomes and toxicities for inoperable early‐stage NSCLC patients receiving SABR, including age ≧ 80 and EGFR mutation status.